Effects of hydrofluoroalkane and dry powder-formulated corticosteroids on sputum inflammatory markers in asthmatic patients

Canadian Respiratory Journal

Volumn 13, Issue 2, 2006, Pages 73-78

  Hauber, Hans Peter ^a   Taha, Rame ^a   Bergeron, Celine ^a   Migounov, Vladimir ^b   Hamid, Qutayba ^a   Olivenstein, Ron ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b 3M Canada Company   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Beclomethasone dipropionate; Bronchial asthma; Budesonide; Eosinophils; Hydrofluoroalkane; Induced sputum

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUORINATED HYDROCARBON; INTERLEUKIN 4; INTERLEUKIN 5;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG MECHANISM; DRY POWDER; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; INHALER; LYMPHOCYTE COUNT; MACROPHAGE ACTIVATION; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TH2 CELL;

EID: 33645937013     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/648392     Document Type: Article

References (24)

1. Hamid Q, Song Y, Kotsimbos TC, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol 1997;100:44-51.
2. Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. Am J Respir Crit Care Med 1995;152:45-52.
3. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992;145:669-74.
4. Esmailpour N, Hogger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997;10:1496-9.
5. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: A cross-over study in healthy volunteers. Chest 2002;122:510-6.
6. Hirst PH, Bacon RE, Pitcairn GR, Silvasti M, Newman SP. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med 2001;95:720-7.
7. Borgstrom L. Deposition patterns with Turbuhaler. J Aerosol Med l994;7(Suppl 1):S49-S53.
8. Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest 1999;115:343-51.
9. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999;104:1215-22.
10. Gershman NH, Liu H, Wong HH, Liu JT, Fahy JV. Fractional analysis of sequential induced sputum samples during sputum induction: Evidence that different lung compartments are sampled at different time points. J Allergy Clin Immunol 1999;104:322-8.
11. Taha R, Hamid Q, Olivenstein R. Fractional analysis of Th2-type cytokines in sequential samples of induced sputum. Can Respir J 2004;11:146-50.
12. Reichel W, Dahl R, Ringdal N, Zetterstrom O, van den Elshout FJ, Laitinen LA. Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma. Int J Clin Pract 2001;55:100-6.
13. Pizzichini E, Pizzichini MM, Efthimiadis A, et al. Indices of airway inflammation in induced sputum: Reproducibility and validity of cell and fluid-phase measurements. Am J Respir Crit Care Med 1996;154:308-17.
14. Hamid Q, Springall DR, Riveros-Moreno V et al. Induction of nitric oxide synthase in asthma. Lancet 1993;342:1510-3.
15. Hamid Q, Wharton J, Terenghi G, et al. Localization of atrial natriuretic peptide mRNA and immunoreactivity in the rat heart and human atrial appendage. Proc Natl Acad Sci USA 1987;84:6760-4.
16. Fahy JV, Boushey HA, Lazarus SC, et al; NHLBI Asthma Clinical Research Network. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am J Respir Crit Care Med 2001;163:1470-5.
17. Alexis NE, Hu SC, Zeman K, Alter T, Bennett WD. Induced sputum derives from the central airways: Confirmation using a radiolabeled aerosol bolus delivery technique. Am J Respir Crit Care Med 2001;164:1964-70.
18. Hauber HP, Gotfried M, Newman K, et al. Effect of HFA-flunisolide on peripheral lung inflammation in asthma. J Allergy Clin Immunol 2003;112:58-63.
19. Olivenstein R, Taha R, Minshall EM, Hamid QA. IL-4 and IL-5 mRNA expression in induced sputum of asthmatic subjects: Comparison with bronchial wash. J Allergy Clin Immunol 1999;103:238-45.
20. Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995;154:4719-25.
21. Fukakusa M, Bergeron C, Tulic MK, et al. Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa. J Allergy Clin Immunol 2005;115:280-6.
22. Holm AF, Godthelp T, Fokkens WJ, et al. Long-term effects of corticosteroid nasal spray on nasal inflammatory cells in patients with perennial allergic rhinitis. Clin Exp Allergy 1999;29:1356-66.
23. Burke C, Power CK, Norris A, Condez A, Schmekel B, Poulter LW. Lung function and immunopathological changes after inhaled corticosteroid therapy in asthma. Eur Respir J 1992;5:73-9.
24. Boulet LP, Turcotte H, Laviolette M, et al. Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Influence of inhaled corticosteroids. Am J Respir Crit Care Med 2000;162:1308-13.